Introduction
============

Esophageal cancer is extremely aggressive and is one of the most fatal cancers worldwide. At present, it ranks eighth in morbidity and sixth in mortality among all cancers in the world.[@b1-ott-9-2919] Clinically, esophageal squamous cell carcinoma (ESCC), as the predominant histological subtype, accounts for \~90% of the total esophageal cancer patients.[@b2-ott-9-2919] Interestingly, the incidence of ESCC is higher in males than in females.[@b3-ott-9-2919] An epidemiological report indicates that the highest rate of ESCC is in Iran, followed by other countries, including the People's Republic of China, South Africa, and France.[@b4-ott-9-2919] The etiology of ESCC appears to be involved with factors such as excessive smoke inhalation and overconsumption of pickled vegetables or hot food. Furthermore, a history of reflux esophagitis is significantly associated with an increased risk of ESCC.[@b5-ott-9-2919] Although the prognosis has improved over the last decade, the 5-year survival rate of ESCC is still only 30%, with tumors recurring within the first year after surgery.[@b6-ott-9-2919] The postoperative recurrence, invasion, and metastasis of ESCC are influenced by relevant factors such as proto-oncogene activation, tumor-suppressor gene inactivation, and abnormal protein expression.

Pim family kinases, including three closely related mammalian serine or threonine kinases (*PIM1*, *PIM2*, and *PIM3*), are small, constitutively active, and highly evolutionarily conserved serine/threonine-specific kinases.[@b7-ott-9-2919],[@b8-ott-9-2919] PIM1 was originally identified from mouse lymphoma samples as a frequently activated gene that was derived from the preferential integration of Moloney leukemia virus into the 3′-untranslated region of the *PIM1* gene.[@b9-ott-9-2919] *PIM1* is located on chromosome 6p21, which has been found to play an oncogenic role in the occurrence of T-cell lymphoma in mice. *PIM1* promotes oncogenesis primarily through suppression of apoptosis, promotion of cell cycle progression, and promotion of genomic instability.[@b10-ott-9-2919],[@b11-ott-9-2919] Overexpression of the PIM1 protein has been implicated in the tumorigenesis of ESCC, gastric cancer, and colon cancer.[@b10-ott-9-2919],[@b12-ott-9-2919],[@b13-ott-9-2919] However, there is little data about the association between *PIM1* polymorphism and biological behavior of ESCC. This study aims to investigate the association between *PIM1* polymorphisms and clinical pathological features of ESCC through detecting the *PIM1* −1 882 A\>T mutation and evaluating PIM1 protein expression in ESCC.

Materials and methods
=====================

Subjects
--------

A total of 168 Chinese patients with ESCC (107 males and 61 females) admitted to the Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Wenzhou Medical University, between September 2012 and September 2014 were enrolled into our study as the case group. Postoperative tumor tissues, adjacent normal tissues, and venous blood (2 mL) were collected from each patient. Patients with ESCC had a mean age of 60.7±12.5 years, with a median age of 61 years. With complete medical records, the ESCC cases with no preoperative chemotherapy or radiotherapy were pathologically confirmed. As defined by the esophageal cancer tumor node metastasis staging manual published by the Union for International Cancer Control/American Joint Committee on Cancer in 2010,[@b14-ott-9-2919] the case group contained 28 patients in stage I, 85 in stage II, 36 in stage III, and 19 in stage IV; 89 with lymph node metastasis and 79 without; and 63 of high differentiation, 50 moderate, and 55 low differentiation. There was no organ-specific metastasis in these patients with ESCC other than lymphatic metastasis. Additionally, we recruited 180 healthy Chinese individuals (121 males and 59 females) with normal esophageal mucosa as the control group and collected tissue specimens and venous blood (2 mL) from each of them. They were aged 61.4±14.7 years, with a median age of 61 years. There were no significant differences in sex or age between the case and control groups (both *P*\>0.05). All paraffin-embedded tissue specimens were confirmed by a pathology specialist. This study was approved by the Ethics Committee of the Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Wenzhou Medical University. All subjects gave informed written consent.

Single nucleotide polymorphism screening and genotype analysis
--------------------------------------------------------------

Genomic DNA was extracted from the venous blood with the phenol/chloroform method.[@b15-ott-9-2919] The *PIM1* promoter region (−2,376 bp\~+10 bp) amplification was conducted with an upstream primer of 5′-GTGGAAAGGCTTTGAATAAA-3′ and a downstream primer of 5′-ATGCAGCCCTCAGTCGTT-3′, designed by Primer 5.0 software (Premier Biosoft, Palo Alto, CA, USA). Direct DNA sequencing (SinoGenoMax Co., Ltd., Beijing, People's Republic of China) was used to screen the single nucleotide polymorphism. DNAman software (version 5.2; Lynnon Biosoft, San Diego, CA, USA) was used to read the screening results and analyze all genotypes with the −1 882 A\>T polymorphism. The total volume of the polymerase chain reaction was 25 μL, containing 100 ng DNA sample and 10 pmol/L primer concentration. The polymerase chain reaction amplification was performed with 5 minutes initial denaturation at 94°C, then 30 cycles of 30 seconds at 94°C, 30 seconds at 57°C, 60 seconds at 72°C, and a final 7 minutes extension at 72°C.

Immunohistochemistry
--------------------

The streptavidin--peroxidase conjugated method was employed for the detection of PIM1 expression. All samples were fixed in 10% formalin, then embedded with paraffin and cut into sections (4 μm each). Throughout deparaffinization and alcoholic dehydration, the sections were immersed in 3% hydrogen peroxide to block endogenous peroxidase for antigen repairing. Rabbit-anti-human *PIM1* polyclonal antibody (Boster Biotech Co., Ltd., Wuhan, People's Republic of China) was added; the sections were incubated at 37°C for 1 hour and then incubated with a biotinylated secondary antibody. Subsequently, diaminobenzidine was added with a coloration time of 1--2 minutes, and then the sections were washed using phosphate-buffered saline (PBS) solution (3×2 minutes). After 1 minute of counterstaining using hematoxylin, the sections were dehydrated and transparent, and they were then sealed with neutral gum. The primary antibody was replaced by PBS as the negative control.

Immunohistochemistry staining results
-------------------------------------

The sections were observed under a light microscope, and the double-blind method was employed to count the positive cells. As a baseline, 300 tumor cells in five high-background fields (×200) were counted. The criteria for the quality controls used for the immunohistochemistry were as follows. Using the couple score and the semiquantitative method, the staining intensity (no staining, 0 points; slight staining, 1 point; moderate staining, 2 points; deep staining, 3 points) and the ratio of positive cells (0%--5%, 0 points; 6%--25%, 1 point; 26%--50%, 2 points; 51%--75%, 3 points; over 75%, 4 points) were determined. The final results were the two scores mentioned earlier multiplied together: 0 points, negative (−); 1--4 points, weak positive (+); 5--8 points, positive (++); and 9--12 points, strong positive (+++).

Statistical analysis
--------------------

Data analysis was performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). The distributions of the allele and genotype frequencies were analyzed with the use of the Hardy--Weinberg equilibrium, which was examined using the *χ*^2^ test when n≥40 but 1≤ T \<5 and checked using Fisher's exact test when n\<40 or T \<1. The odds ratio with 95% confidence interval was calculated to estimate the associations between *PIM1* polymorphism and the risk of ESCC. Moreover, risk factors, such as the degree of tumor differentiation, invasion depth, and clinical stage, were examined using a rank test. *P*\<0.05 was considered statistically significant.

Results
=======

Distributions of genotype and allele of *PIM1* polymorphism and the risk of ESCC
--------------------------------------------------------------------------------

The distribution of the allele and genotype of *PIM1* −1 882 A\>T in the case and control groups agreed with the Hardy--Weinberg equilibrium (both *P*\>0.05). The frequencies of allele −1 882 A in the case and control groups were significantly different (*P*\<0.05) at 92.9% and 87.8%, respectively. The frequencies of the AA, TT, and AT genotypes were, respectively, 86.3%, 0.6%, and 13.1% in the case group and 77.2%, 1.7%, and 21.1% in the control group, which also demonstrated a significant difference between these two groups (all *P*\<0.05). We also found that AT + TT carriers had a lower risk of ESCC than AA carriers (odds ratio =0.538, 95% confidence interval =0.307--0.943, *P*\<0.05) ([Table 1](#t1-ott-9-2919){ref-type="table"}).

*PIM1* polymorphism and clinicopathological features of ESCC
------------------------------------------------------------

The distribution of the *PIM1* polymorphism changed remarkably, which influenced the invasion depth, degree of differentiation, and lymphatic metastasis of ESCC (all *P*\<0.05). However, there was no significant difference in the frequency of the *PIM1* polymorphism with regard to sex, age, clinical stage, or tumor size according to the rank test (all *P*\>0.05) ([Table 2](#t2-ott-9-2919){ref-type="table"}).

PIM1 protein expression in ESCC tissues and adjacent normal tissues
-------------------------------------------------------------------

The PIM1 protein was primarily expressed in the cell cytoplasm and membrane. Staining for the PIM1 protein in ESCC tissues was uniformly brown-yellow or sepia, with a positive rate of 74.4% (125/168). However, a small amount of PIM1 protein expression was observed in the adjacent normal tissues, which were colorless or light yellow, and the positive rate was 23.2% (39/168), which was significantly lower than that in the corresponding ESCC tissue (*P*\<0.05) ([Table 3](#t3-ott-9-2919){ref-type="table"}; [Figure 1](#f1-ott-9-2919){ref-type="fig"}).

PIM1 protein expression and clinicopathological features of ESCC
----------------------------------------------------------------

PIM1 protein expression was associated with lymphatic metastasis of ESCC (*P*\<0.05). However, there was no significant difference in PIM1 protein expression with regard to sex, age, invasion depth, degree of differentiation, clinical stage, or tumor size according to the rank test (all *P*\>0.05) ([Table 4](#t4-ott-9-2919){ref-type="table"}).

Association between *PIM1* polymorphism and PIM1 protein expression
-------------------------------------------------------------------

As shown in [Table 5](#t5-ott-9-2919){ref-type="table"}, the rate of PIM1 protein expression was significantly different (*P*\<0.05) among the AA (77.9%), AT (54.6%), and TT (0) *PIM1* genotypes. The AA genotype exhibited the highest level of positive protein expression, suggesting that the *PIM1* polymorphism is associated with PIM1 protein expression.

Discussion
==========

ESCC is the most prevalent pathological type of esophageal cancer in both Western and Asian countries.[@b16-ott-9-2919] Recently, progress has been made in diagnosis and therapeutic options for ESCC, particularly in exploring its relationship with gene polymorphisms.[@b17-ott-9-2919],[@b18-ott-9-2919] *PIM1* is a proto-oncogene that encodes a serine/threonine kinase with multiple cellular functions involving the regulation of cell apoptosis and progression, as well as transcription through various signaling pathways, including the STAT3 → PIM1 → NFkappaB stress response pathway and signaling pathways downstream of Akt.[@b19-ott-9-2919]--[@b21-ott-9-2919] Accumulating evidence has demonstrated that *PIM1* plays an important role in tumor progression, including colon cancer, laryngeal cancer, lymphocytic leukemia, and head and neck squamous cell carcinomas.[@b13-ott-9-2919],[@b22-ott-9-2919]--[@b24-ott-9-2919] In our study, we found that *PIM1* polymorphism and alteration of PIM1 expression participated in the development of ESCC and were closely related to the clinicopathological features of ESCC, revealing that *PIM1* could be useful for predicting biological behavior in patients with ESCC. Kim et al[@b25-ott-9-2919] found that the T-C-T-C haplotypes of *PIM1* (−1,196 T\>C, IVS4 +55 T\>C, IVS4 +1,416 T\>A, and +3,684 C\>A) were associated with an increased risk of lung cancer. Akagi et al[@b26-ott-9-2919] found that the E135K mutation of *PIM1* may be associated with acute myeloid leukemia. *PIM1* −1 882 A\>T is a novel single nucleotide polymorphism that has not been reported. However, we found that individuals with the AA genotype exhibited the highest positive protein expression, and there was just one patient carrying the TT genotype among the 168 patients with ESCC, suggesting that the *PIM1* polymorphism was associated with PIM1 protein expression. A possible reason is that *PIM1* polymorphism can reduce PIM1 protein expression levels. Our study first explored the *PIM1* −1 882 A\>T polymorphism and found that the AA genotype and A allele might contribute to the development and progression of ESCC, while the −1 882 A\>T mutation (TT genotype and T allele) might decrease the risk of ESCC.

Because we measured the PIM1 expression levels in both the ESCC tumor tissues and the adjacent normal tissues, we discovered that the PIM1 protein is mainly expressed in the cytoplasm and cell membrane, and its expression in the ESCC tumor tissues was significantly higher when compared with the adjacent normal tissues. The PIM protein kinases are overexpressed in multiple human malignancies, including prostate cancer, lymphoma, leukemia, and pancreatic ductal adenocarcinoma and breast tumors.[@b27-ott-9-2919]--[@b31-ott-9-2919] Additionally, the histologic grade, clinicopathological staging, and lymphatic metastasis are the most crucial prognostic factors for determining clinical outcomes in ESCC and, thus, clinical and pathological parameters, such as age, sex, histologic grade, clinical staging, tumor size, and lymph node metastasis, were used to investigate the expression of PIM1 in the progression of ESCC. In our study, the levels of positive PIM1 protein staining in ESCC tissues were significantly higher than those in the adjacent normal group and were influenced by the lymphatic metastasis of ESCC, which might indicate that the overexpression of PIM1 is correlated with the progression of ESCC. Liu et al[@b12-ott-9-2919] reported the overexpression of PIM1 in patients with ESCC, suggesting that PIM1 may act as a molecular marker for predicting the prognosis of patients with ESCC.

Interestingly, our study also found that the invasion depth, degree of differentiation, and lymphatic metastasis were also associated with the distribution of the *PIM1* −1 882 A\>T genotype. It is possible that the *PIM1* −1 882 A\>T polymorphism affects the combination of the promoter region and signal factor, leading to an increase in PIMI expression and further inhibiting the malignant transformation of cells.

Our research explored the *PIM1* polymorphism and PIM1 expression in the progression of ESCC and was the first to study the possible effect of the novel −1 882 A\>T single nucleotide polymorphism on the development of ESCC. Collectively, our study demonstrated that the *PIM1* −1 882 A\>T polymorphism may help to reduce the risk of ESCC, and PIM1 expression may also serve as an index to detect biological behavior in the Asian population. Given the complexity of the role of gene functions in ESCC, further studies on *PIM1* polymorphisms with a larger sample size or greater ethnic diversity are needed to help evaluate the utility of *PIM1* as a therapeutic target for the treatment of ESCC.
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###### 

Genotype and allele frequency and risks of *PIM1* polymorphism in the case and control groups

  Allele/genotype   Case group (n=168)   Normal group (n=180)   *P*-value   OR (95% CI)           
  ----------------- -------------------- ---------------------- ----------- ------------- ------- ----------------------
  AA                145                  86.3                   139         77.2                  Ref
  AT                22                   13.1                   38          21.1          0.042   0.555 (0.313--0.986)
  TT                1                    0.6                    3           1.7           0.301   0.320 (0.033--3.111)
  TT + AT           23                   13.7                   41          22.8          0.029   0.538 (0.307--0.943)
  A                 312                  92.9                   316         87.8                  Ref
  T                 24                   7.1                    44          12.2          0.024   0.552 (0.328--0.931)

**Abbreviations:** CI, confidence interval; OR, odds ratio; Ref, reference.

###### 

*PIM1* polymorphism and clinicopathological features of esophageal squamous cell carcinoma

  Parameters                     Number   *PIM1* genotype   *P*-value   
  ------------------------------ -------- ----------------- ----------- -------
  Sex                                                                   0.870
   Male                          107      15                92          
   Female                        61       8                 53          
  Age                                                                   0.237
   ≥60 years old                 113      13                100         
   \<60 years old                55       10                45          
  Histological differentiation                                          0.021
   High                          63       8                 55          
   Medium                        50       12                38          
   Low                           55       3                 52          
  Invasion depth                                                        0.039
   T1                            51       2                 49          
   T2                            69       10                59          
   T3                            26       7                 19          
   T4                            22       4                 18          
  Tumor size                                                            0.983
   Diameter ≥3 cm                80       11                69          
   Diameter \<3 cm               88       12                76          
  Clinical stage                                                        0.770
   I                             28       3                 25          
   II                            85       14                71          
   III                           36       4                 32          
   IV                            19       2                 17          
  Lymphatic metastasis                                                  0.020
   With metastasis               89       7                 82          
   Without metastasis            79       16                63          

###### 

PIM1 protein expression in the ESCC tissues and adjacent normal tissues

  Group                     Number   PIM1 expression   Positive rate (%)   *P*-value               
  ------------------------- -------- ----------------- ------------------- ----------- ---- ------ ---------
  ESCC tissues              168      43                22                  49          54   74.4   \<0.001
  Adjacent normal tissues   168      129               17                  14          8    23.2   

**Note:** − = negative; + = weak postitive; ++ = positive; +++ = strong positive.

**Abbreviation:** ESCC, esophageal squamous cell carcinoma.

###### 

PIM1 protein expression and clinical pathologic features of esophageal squamous cell carcinoma

  Factor                         Number   Protein expression of *PIM1*   *P*-value   
  ------------------------------ -------- ------------------------------ ----------- -------
  Sex                                                                                0.337
   Male                          107      77                             30          
   Female                        61       48                             13          
  Age                                                                                0.064
   ≥60 years old                 113      89                             24          
   \<60 years old                55       36                             19          
  Histological differentiation                                                       0.550
   High                          63       45                             18          
   Medium                        50       40                             10          
   Low                           55       40                             15          
  Invasion depth                                                                     0.773
   T1                            51       39                             12          
   T2                            69       49                             20          
   T3                            26       21                             5           
   T4                            22       16                             6           
  Tumor size                                                                         0.590
   Diameter ≥3 cm                80       58                             22          
   Diameter \<3 cm               88       67                             21          
  Clinical stage                                                                     0.075
   I                             28       20                             8           
   II                            85       62                             23          
   III                           36       32                             4           
   IV                            19       11                             8           
  Lymphatic metastasis                                                               0.041
   With metastasis               89       72                             17          
   Without metastasis            79       53                             26          

###### 

Association between *PIM1* polymorphism and PIM1 protein expression

  Genotype   N (%)        Positive protein expression (%)   *P*-value
  ---------- ------------ --------------------------------- -----------
  AA         145 (86.3)   113 (77.9)                        0.015
  AT         22 (13.1)    12 (54.6)                         
  TT         1 (0.6)      0 (0)                             
